IMMUNOLOGY2026™ Conference Recordings For Attendees-Optimizing T Cell Priming Using TLR4/9 Combination Adjuvant For Robust Cell-Mediated Immunity Against Influenza

Optimizing T Cell Priming Using TLR4/9 Combination Adjuvant For Robust Cell-Mediated Immunity Against Influenza

Video Transcription

Video Summary

Elise Nguyen presented research on improving flu vaccines by adding TLR4 and TLR9 agonists to a subunit vaccine. Her lab developed IVAX-1, combining CPG, MPLA, and the oil-in-water emulsion Atavax. In mouse H5N1 studies, IVAX-1 rapidly induced strong interferon-gamma-producing CD4 and CD8 T-cell responses, with signs of clonal expansion in lymph nodes. A single dose also protected mice from lethal influenza challenge, reduced weight loss, and lowered lung viral titers by 44,000-fold compared with controls. She concluded that this adjuvant combination strengthens cell-mediated immunity and improves viral clearance, with manageable short-term inflammation.

Meta Tag

Date April 19, 2026 10:30 AM - 10:45 AM

Room 102

Session Innovations in Vaccine Adjuvants and Immune Modulation

Speaker Dan Nguyen

Track Vaccines and Immunotherapy (VAC)

Year 2026

Keywords

IVAX-1

TLR4 agonist

TLR9 agonist

influenza vaccine adjuvant

cell-mediated immunity

April 19, 2026 10:30 AM - 10:45 AM

102

Innovations in Vaccine Adjuvants and Immune Modulation

Dan Nguyen

Vaccines and Immunotherapy (VAC)

2026